Alkermes

Alkermes, after arbitration win over J&J, jacks up revenue forecast by $425M
Alkermes, after arbitration win over J&J, jacks up revenue forecast by $425M
Fierce Pharma
Alkermes
JNJ
nanocrystals
Flag link:
Alkermes to hive off oncology business
Alkermes to hive off oncology business
Pharma Letter
Alkermes
oncology
spinoffs
Flag link:
With millions on the line, Alkermes, J&J start arbitration over drug delivery tech dispute
With millions on the line, Alkermes, J&J start arbitration over drug delivery tech dispute
Fierce Pharma
Alkermes
JNJ
Janssen
drug delivery
Nanocrystal
Flag link:
J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'
J&J tries to back out of nanoparticle license agreement — but Alkermes says 'not so fast'
Endpoints
JNJ
Alkermes
nanoparticles
Flag link:
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Motley Fool
Biogen
Alkermes
Alpine Immune Sciences
Flag link:
ASCO 2021 – Alkermes’s disappointment hones melanoma niche focus
ASCO 2021 – Alkermes’s disappointment hones melanoma niche focus
EP Vantage
ASCO 2021
Alkermes
melanoma
nemvaleukin alfa
Flag link:
After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi
After FDA approval, Alkermes plans soft launch for antipsychotic Lybalvi
Pharmaforum
Alkermes
FDA
antipsychotic
Lybalvi
Flag link:
Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug
Alkermes prepares for uncertain launch as FDA finally clears schizophrenia drug
Biopharma Dive
Alkermes
FDA
schizophrenia
bipolar disorder
Lybalvi
Flag link:
As Alkermes shines light on early cancer, neuro assets, biotech searches for collabs, strategic ops
As Alkermes shines light on early cancer, neuro assets, biotech searches for collabs, strategic ops
Fierce Biotech
Alkermes
R&D
cancer
immuno-oncology
Flag link:
Why Alkermes' Q4 Results Were Better Than They Might Seem
Why Alkermes' Q4 Results Were Better Than They Might Seem
Motley Fool
Alkermes
earnings
Flag link:
Alkermes sees swift turnaround for rejected schizophrenia med as FDA accepts resubmission
Alkermes sees swift turnaround for rejected schizophrenia med as FDA accepts resubmission
Fierce Biotech
Alkermes
ALKS 5461
ALKS 3831
FDA
drug manufacturing
schizophrenia
Flag link:
Drug rejections rise as Covid-19 bites
Drug rejections rise as Covid-19 bites
EP Vantage
COVID-19
drug approvals
Alkermes
ALKS 3831
pandemic
regulatory inspections
Flag link:
Alkermes is handed a CRL for ‘3831, marking another setback on the R&D front
Alkermes is handed a CRL for ‘3831, marking another setback on the R&D front
Endpoints
Alkermes
ALKS-3831
FDA
CRL
Flag link:
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
Xconomy
Alkermes
FDA
advisory panels
ALKS 3831
schizophrenia
bipolar disorder
Flag link:
FDA Raises Concern Over Opioid Abuse Related to Alkermes' Schizophrenia Drug
FDA Raises Concern Over Opioid Abuse Related to Alkermes' Schizophrenia Drug
BioSpace
Alkermes
FDA
schizophrenia
opioids
ALKS 3831
Flag link:
5 FDA approval decisions to watch in the 4th quarter
5 FDA approval decisions to watch in the 4th quarter
BioPharma Dive
FDA
drug approvals
vaccines
Pfizer
Moderna Therapeutics
COVID-19
Regeneron
EB3
ebola virus
Alkermes
ALKS-3831
schizophrenia
bipolar disorder
Bristol-Myers Squibb
liso-cel
non-Hodgkin lymphoma
roxadustat
FibroGen
chronic kidney disease
Flag link:
Esmo 2020 – can Alkermes succeed where Nektar failed?
Esmo 2020 – can Alkermes succeed where Nektar failed?
EP Vantage
Alkermes
ESMO
ALKS 4230
melanoma
Flag link:
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
Fierce Biotech
Alkermes
immuno-oncology
ESMO
ALKS 4230
Keytruda
Flag link:
Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions
Virtual FDA AdComm for Alkermes' ALKS 3831 adds new focus on drug-drug interactions
Fierce Biotech
Alkermes
schizophrenia
bipolar disorder
FDA
ALKS 3831
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:

Pages